OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2025
(4)
2021
(3)
2024
(2)
2022
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861
|
biostudies-literature
Cite
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study.
Not available
S-EPMC11578795
|
biostudies-literature
Cite
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792
|
biostudies-literature
Cite
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Not available
S-EPMC11408082
|
biostudies-literature
Cite
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Not available
S-EPMC11869088
|
biostudies-literature
Cite
Sex Differences in Long COVID.
Not available
S-EPMC11755195
|
biostudies-literature
Cite
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219
|
biostudies-literature
Cite
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808
|
biostudies-literature
Cite
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995
|
biostudies-literature
Cite
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets